Corixa, Medicis and Genesis Announce Phase II Trial Evidence of Clinical Benefit and Safety At 15-Microgram Dose.
Business Wire › February 14, 2001
Linked as:
Extract
Corixa, Medicis and Genesis Announce Phase II Trial Evidence of Clinical Benefit and Safety At 15-Microgram Dose.
Health/Medical Writers
SEATTLE & SCOTTSDALE, Ariz. & AUCKLAND, New Zealand-- (BW HealthWire)--Feb. 14, 2001 Corixa Corporation (Nasdaq:CRXA), a research- and development-based biotechnology company, Medicis Pharmaceutical Corporation (NYSE:MRX) and Genesis Research and Development of New Zealand today announced preliminary U.S. Phase II clinical trial results on Corixa's immunotherapeutic psoriasis treatment, PVAC(TM). Analysis of the results of a four-arm, randomized, double-blinded, controlled study in the United States, suggests that PVAC therapy at a dose of 15 micrograms per injection provides appreciable clinical benefit in patients with moderate to severe psoriasis. Corixa announced in August 2000 th...See the full content of this document
Sponsored links
